<DOC>
	<DOC>NCT02097745</DOC>
	<brief_summary>This study will assess the long-term safety and efficacy of repeating treatment with MabThera, in combination with methotrexate and steroids, in patients who were previously randomized into MabThera study WA17042. The anticipated time on study treatment is until Mabthera is available on the local market and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>adult patients 1880 years of age with active RA; patients who participated in MabThera study WA17042, and completed to at least the Week 24 visit; eligible for retreatment, based on clinical symptoms; patients of reproductive potential must be using reliable contraceptive methods. patients who participated in MabThera study WA17042 but withdrew into the safety followup; current treatment with any other diseasemodifying antirheumatic drug (apart from methotrexate), or any antiTNFalfa, antiIL1, or other biologic therapies; development of any new contraindications to receiving MabThera; women who are pregnant or breastfeeding.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>